🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

3,067 results for “Hospital” Clear

  1. Herceptin 150 mg powder for concentrate for solution for infusion, DS-8201a, Perjeta 420 mg concentrate for solution for infusion, Paclitaxel 6 mg/ml concentrate for solution for infusion

    Ningbo Cancer Hospital

    Early stage HER2-positive breast cancer

    phase 3 small molecule active

    1 trial

  2. Houyanqing Oral Liquid

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Nasopharyngeal Cancinoma (NPC)

    phase 3 small molecule active

    1 trial

  3. Human Norovirus Bivalent (GⅠ.1/GⅡ.4)Vaccine，Recombinant (Hansenula polymorpha)

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Norovirus Infections

    phase 3 mab completed

    1 trial

  4. Hyperthermic Intraperitoneal Chemotherapy (HIPEC)

    The First People's Hospital of Lianyungang

    Gastric Cancer

    phase 3 other active

    1 trial

  5. IAC regimen

    The First People's Hospital of Lianyungang

    Acute Myeloid Leukemia

    phase 3 small molecule completed

    1 trial

  6. IAE0972+ Methotrexate

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    NPC

    phase 3 mab active

    1 trial

  7. IMFINZI 50 mg/mL concentrate for solution for infusion., Futibatinib, Zercepac 150 mg powder for concentrate for solution for infusion., Braftovi 75 mg hard capsules, Mektovi 15 mg film-coated tablets, JZP598, Zejula 100 mg hard capsules, Nerlynx 40 mg film-coated tablets, IVOSIDENIB, CISPLATIN, PEMBROLIZUMAB, GEMCITABINE

    Ningbo Cancer Hospital

    Advanced Biliary Cancer (ABC)

    phase 3 small molecule active

    1 trial

  8. IMFINZI 50 mg/mL concentrate for solution for infusion., IMJUDO 20 mg/ml concentrate for solution for infusion., IMJUDO 20 mg/ml concentrate for solution for infusion., IMJUDO 20 mg/ml concentrate for solution for infusion., IMFINZI 50 mg/mL concentrate for solution for infusion., IMFINZI 50 mg/mL concentrate for solution for infusion., OXALIPLATIN, GEMCITABINE, IMFINZI 50 mg/mL concentrate for solution for infusion., IMJUDO 20 mg/ml concentrate for solution for infusion.

    Ningbo Cancer Hospital

    Patients with hepatocellular carcinoma with high tumor burden.

    phase 3 small molecule active

    1 trial

  9. IMIPENEM, CILASTATIN AND RELEBACTAM, AMIKACIN , TIGECYCLINE , Nacubactam, AZACTAM 1 g, poudre et solution pour usage parentéral, COLISTIN , Cefepime Panpharma, 2 g, proszek do sporządzania roztworu do wstrzykiwań lub infuzji

    Lacuna Pharma Pty Ltd

    Complicated urinary tract infection (cUTI), acute uncomplicated pyelonephritis (AP), hospital acquired bacterial pneumonia (HABP), ventilator-associated bacterial pneumonia (VABP), and complicated intra-abdominal infection (cIAI)

    phase 3 small molecule active

    1 trial

  10. Iloprost

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Pulmonary Arterial Hypertension

    phase 3 small molecule active

    1 trial

  11. Immunonutrition （Su yusu)

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Gastrointestinal Tumors

    phase 3 small molecule active

    1 trial

  12. Inactivated Poliomyelitis Vaccine (Sabin strains)

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Poliomyelitis

    phase 3 mab completed

    2 trials

  13. Individualized Elective Neck Irradiation

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Nasopharyngeal Carcinoma

    phase 3 other active

    1 trial

  14. Induction Chemotherapy

    The First People's Hospital of Lianyungang

    Locally Advanced Nasopharyngeal Carcinoma

    phase 3 small molecule active

    1 trial

  15. Infrared ray heat treatment

    The First People's Hospital of Lianyungang

    Liver Cirrhosis

    phase 3 other active

    1 trial

  16. Intermediate-dose Cytarabine in Combination with Venetoclax

    The First People's Hospital of Lianyungang

    Acute Myeloid Leukemia (AML)

    phase 3 small molecule active

    1 trial

  17. Intervention

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    HIV

    phase 3 other active

    1 trial

  18. Intra-arterial thrombolysis

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Acute Ischemic Stroke

    phase 3 other active

    1 trial

  19. Intravenous methylene blue administration

    Hospital Authority, Hong Kong

    Severe Sepsis

    phase 3 small molecule active

    1 trial

  20. Intravenous nicardipine hydrochloride

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Intracerebral Hemorrhage

    phase 3 small molecule terminated

    1 trial

  21. Intravenous rhTNK-tPA

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Stroke, Acute Ischemic

    phase 3 small molecule active

    1 trial

  22. Intravenous thrombolysis plus tirofiban

    Hospital Authority, Hong Kong

    Acute Ischemic Stroke

    phase 3 small molecule completed

    1 trial

  23. Intravenous thrombolysis plus tirofiban

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Acute Ischemic Stroke

    phase 3 small molecule completed

    1 trial

  24. JEVTANA 60 mg concentrate and solvent for solution for infusion.

    Ningbo Cancer Hospital

    Patients with localized prostate cancer and high-risk features of relapse.

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources